Acadia Pharmaceuticals Inc [ACAD] stock is trading at $22.80, up 2.98%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ACAD shares have gain 2.70% over the last week, with a monthly amount glided 2.43%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Acadia Pharmaceuticals Inc [NASDAQ: ACAD] stock has seen the most recent analyst activity on May 21, 2025, when Deutsche Bank upgraded its rating to a Buy but kept the price target unchanged to $35 for it. Previously, Deutsche Bank started tracking the stock with Hold rating on February 11, 2025, and set its price target to $22. On January 03, 2025, downgrade downgraded it’s rating to Neutral and revised its price target to $20 on the stock. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $20 on August 07, 2024. BMO Capital Markets started tracking with a Outperform rating for this stock on June 27, 2024, and assigned it a price target of $31. In a note dated March 12, 2024, Needham reiterated an Buy rating on this stock and revised its target price from $36 to $32.
Acadia Pharmaceuticals Inc [ACAD] stock has fluctuated between $13.40 and $25.23 over the past year. Currently, Wall Street analysts expect the stock to reach $25.6 within the next 12 months. Acadia Pharmaceuticals Inc [NASDAQ: ACAD] shares were valued at $22.80 at the most recent close of the market. An investor can expect a potential return of 12.28% based on the average ACAD price forecast.
Analyzing the ACAD fundamentals
Acadia Pharmaceuticals Inc [NASDAQ:ACAD] reported sales of 996.28M for the trailing twelve months, which represents a growth of 18.70%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.27%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.2, Equity is 0.35 and Total Capital is 0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 22.23 points at the first support level, and at 21.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.10, and for the 2nd resistance point, it is at 23.41.
Ratios To Look Out For
For context, Acadia Pharmaceuticals Inc’s Current Ratio is 2.88. Further, the Quick Ratio stands at 2.80, while the Cash Ratio is 0.72. Considering the valuation of this stock, the price to sales ratio is 3.83, the price to book ratio is 4.98 and price to earnings (TTM) ratio is 16.60.
Transactions by insiders
Recent insider trading involved Brege Laura, Director, that happened on Jun 04 ’25 when 14446.0 shares were sold. Director, LAURA BREGE completed a deal on Jun 04 ’25 to buy 14446.0 shares. Meanwhile, PRINCIPAL ACCOUNTING OFFICER Kihara James sold 4000.0 shares on May 16 ’25.
